Three abstracts highlighting the company’s recent research into ocular diseases and its lead gene therapy treatment SPVN06 have been accepted for the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, to be held virtually from 1-7 May.
Paris, March 19, 2021 – SparingVision (“the Company”), a genomic medicine company developing vision saving treatments for ocular diseases, announces today that three abstracts highlighting the company’s recent research into ocular diseases and its lead gene therapy treatment SPVN06 have been accepted for the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, to be held virtually from 1-7 May. The three abstracts will be given as poster presentations for which the details can be found below.
Title: SPVN06, a Novel Mutation-Independent AAV-based Gene Therapy, Protects Cone Degeneration in a Pig Model of Retinitis Pigmentosa
Date and Time: May 3, 2021 from 11:15 AM to 1:00 PM EDT
Presenter: Dr. Jennifer Noel, University of Louisville
Session Title: Drug delivery and Gene Therapy
Title: Correlations between progression markers in rod-cone dystrophy due to mutations in RHO, PDE6A, or PDE6B
Date and Time: May 3, 2021 from 4:30 PM to 6:15 PM EDT
Presenter: Dr. Daniel Chung, Chief Medical Officer, SparingVision
Session Title: Visual Impairment – Assessment and Measurement
Title: A 1-Month Toxicology and Biodistribution NHP Pilot Study Evaluating a Single Subretinal Bilateral Administration of SPVN06 – A Novel AAV-Based Gene Therapy for the Treatment of Rod-Cone Dystrophies Agnostic of the Causative Mutation
Date and Time: May 5, 2021 from 2:45 PM to 4:30 PM EDT
Presenter: Dr. Melanie Marie, SparingVision
Session Title: AMD and retinal physiology
SparingVision is a genomic medicines company, translating pioneering science into vision-saving treatments.
Founded to advance over 20 years of world-leading ophthalmic research from its scientific founders at the Paris Vision Institute, SparingVision is leading a step shift in how ocular diseases are treated, moving beyond single gene correction therapies. At the heart of this is a pipeline of gene independent treatments for rod-cone dystrophies. Lead products, SPVN06 and SPVN20, address mid and late stages of retinitis pigmentosa (RP)respectively. RP is the most common inherited retinal disease affecting two million people worldwide. These novel medicines could form the basis of a suite of new sight-saving treatments with potential applications across many other retinal diseases, regardless of genetic cause.
The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible.
SparingVision has raised €60 million to date and its investors include 4BIO Capital, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. For more information, please visit www.sparingvision.com.